Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
about
The p53-estrogen receptor loop in cancerPrognostic and predictive value of p53 and p21 in breast cancer.The relationship between prognostic and predictive factors in the management of breast cancer.Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalThe Role of c-erbB-2 as a predictive factor in breast cancer.Ki67 protein: the immaculate deception?Prognostic and predictive value of HER2/neu oncogene in breast cancer.Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases.p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.Ki-67 biomarker in breast cancer of Indian womenEffect of Crocin on Cell Cycle Regulators in N-Nitroso-N-Methylurea-Induced Breast Cancer in RatsPrimary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.p21(WAF1) expression and endocrine response in breast cancer.Mechanisms of Traditional Chinese Medicine in the Treatment of Mammary Gland Hyperplasia.Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.Treatment Options For Postmenopausal Women with Tamoxifen-Resistant Advanced Breast CancerPredictors of response to second-line endocrine therapy for breast cancer
P2860
Q27027865-59824921-7711-495B-B653-A85E75B4DC9BQ33538430-A0620C9D-035A-44FF-9A3D-482C8290CDC9Q33538455-EAB16E63-7B82-45C8-A94F-E7CD34DD099DQ33842800-AFD91178-D210-4C1D-A7B5-65EB1C924626Q33939753-32212F9E-8969-4E6B-84E5-B7E4400A2DC1Q34415264-36D9C2D7-5B38-4D58-9B52-7FAB1FF78B14Q34570709-277EEC4B-03CC-4B96-A550-AAAF86084706Q34954864-FD0A69B4-017D-48DE-B03C-3C73D21B1695Q35012858-88BB9BB2-C310-4F84-82BE-8E081C6769D2Q35161695-8F0C669E-D7B5-44AE-81A0-D9AAED9E6E9AQ35588605-0FB27DE1-5ABF-48D4-A433-CE296EA17639Q35605783-8049D4E0-A6A5-4576-BCFA-32E16B5A14E7Q35913434-529AD48E-DB60-4D28-8CDF-2D8FA169C568Q36274411-6EB90AAB-7F6A-4338-A988-975F3757028EQ36615222-5097DF65-4023-442A-9D59-4F29F8CC7EB4Q36617556-EF91B4A6-B6BB-4CB3-AAF7-4C86FD2A7D07Q36621098-019FCC67-5C0E-4F1C-85A0-21D7077BD8ABQ36860992-B387EE98-7432-40ED-AD3F-8A99696B3557Q38468028-CE16F693-7CE2-4180-A2C3-ABAA911342BDQ39209042-76C2BDE6-B7F0-423A-A325-C57DA8BFD89BQ43266611-8E85A5B5-DBEC-45BC-9BE7-3472A0341833Q44971108-11B6D6A2-BF69-44A8-915D-EE6BC1744040Q54065729-5073E628-4251-4BED-AC8C-B212F6034AC4Q54115075-AA7AA546-8DFC-49EA-BC18-5635BFEAA24FQ54953677-A2336628-DA40-4CCB-AFCB-E57629D5CC74Q58834586-221C29E0-7745-4769-94F9-DA773C6C47F6Q58834601-C9DBE5EA-19C7-43CD-BC77-4A68E9556649
P2860
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@ast
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@en
type
label
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@ast
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@en
prefLabel
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@ast
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@en
P2093
P2860
P356
P1476
Expression of ras p21, p53 and ...... o first line hormonal therapy.
@en
P2093
Eliopoulos A
Nicholson RI
Robertson JF
Spandidos D
P2860
P2888
P304
P356
10.1038/BJC.1995.497
P407
P50
P577
1995-11-01T00:00:00Z